Sonivie

Rosh Ha'ayin, IsraelFounded 201411–50 employeessonivie.comLinkedIn

SoniVie is a medical device company developing TIVUS, an investigational intravascular treatment for patients with pulmonary arterial hypertension (PAH). The procedure is designed to be performed as part of a routine right heart catheterization.

Visit sonivie.com ↗

Founded: 2014
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

SoniVie’s most consequential milestone was its announced acquisition by Boston Scientific on Mar 3, 2025 for $540 million, with the transaction described financially as $400 million upfront plus up to $200 million tied to a regulatory milestone. The deal shifted the company from an independently financed medtech developer toward integration with a major cardiovascular-device platform. Its most recent financing preceded that transaction: SoniVie raised a $60 million Series C on Jan 9, 2023 led by Andera Partners. Governance also evolved before the acquisition. The company added board members in January 2023 and appointed Raymond W. Cohen as Chairman of the Board in November 2024. The company’s recent profile is therefore defined more by strategic ownership and leadership changes than by a clearly documented commercial launch.

Market position

SoniVie operates in a specialized segment of interventional cardiovascular medtech, developing TIVUS, an investigational intravascular ultrasound-based approach for pulmonary arterial hypertension. Its positioning differs from conventional drug-focused PAH treatment by targeting denervation through a catheter-based procedure intended to fit within a routine right heart catheterization. The company also has related TIVUS applications under development for renal artery denervation and chronic obstructive pulmonary disease, although the pulmonary hypertension program is the clearest current focus. The profile does not identify a verified set of direct named competitors, so relative market-share claims would be premature. Instead, SoniVie’s strongest competitive signal is strategic validation through Boston Scientific’s 2025 acquisition and the backing of specialist investors including Andera Partners, Omega Funds, Supernova Invest, Accelmed, HeartX, and TechWald Holding. The principal market constraint remains clinical and regulatory execution: TIVUS is described as investigational, and adoption will depend on evidence of safety, efficacy, procedural practicality, and reimbursement in a narrowly defined patient population.

Growth & opportunities

SoniVie’s trajectory shows a long development cycle followed by a major strategic inflection point. Founded in 2014, the company raised a $2.5 million Seed round in 2015, a $150,000 Venture Round in 2021, and a $60 million Series C on Jan 9, 2023. The financing history indicates that the company remained focused on advancing a capital-intensive medical-device platform rather than pursuing rapid commercial expansion. Its development scope broadened around the TIVUS platform, spanning pulmonary artery denervation, renal artery denervation, and a potential COPD application. Leadership activity also increased: new board members were added in January 2023, followed by Raymond W. Cohen’s appointment as Chairman in November 2024. The acquisition announcement on Mar 3, 2025 for up to $600 million in total consideration marks the clearest inflection point, providing access to Boston Scientific’s resources while potentially changing SoniVie’s standalone growth profile.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

What makes Sonivie distinct

reccy insights

What makes Sonivie distinct

01Focuses on pulmonary arterial hypertension, a serious and specialized cardiovascular condition.
02TIVUS is designed for delivery through an intravascular approach.
03The investigational treatment may be performed as part of a routine right heart catheterization.
04The company is focused on advancing an interventional treatment option for PAH patients.

Technology & products3

Technology & products

TIVUS for Renal Denervation
A catheter-based technology using non-focused ultrasound for renal artery denervation aimed at treating resistant hypertension.
TIVUS for Pulmonary Artery Denervation
An investigational device for pulmonary artery denervation to treat pulmonary hypertension, utilizing therapeutic intravascular ultrasound.
TIVUS for Chronic Obstructive Pulmonary Disease
A device in development for total lung denervation in patients with COPD to potentially improve exercise tolerance by reducing nerve activity.

About Sonivie

Products: TIVUS for Renal Denervation, TIVUS for Pulmonary Artery Denervation, TIVUS for Chronic Obstructive Pulmonary Disease
Leadership: Raymond W. Cohen, Chairman of the Board
Focus areas: Medical devices, pulmonary arterial hypertension, cardiovascular, intravascular therapy, interventional cardiology, clinical research, therapeutics
Headquarters: Rosh Ha'ayin, Israel
Founded: 2014
Employees: 11–50
Patents granted: 22 (Crunchbase)
Trademarks: 3